Case Review: Progression in Follicular Lymphoma
Case Review: Progression in Follicular Lymphoma
Case:A 70-Year-Old Man With Follicular Lymphoma
H & P:
- A 70-year-old man presents with night sweats and general fatigue
- PMH: hypertension, no history of MACE
- PE: Groin is tender to touch, no tenderness in abdomen
- Initially diagnosed with bilateral axillary contiguous stage II FL 5.5 years ago
- Grade 2 FL, 4 masses (each >3 cm)
- FLIPI status: high risk
Current biopsy and labs:
- Biopsy: grade 2 FL without transformation
- ECOG performance status: 1
- Hematologic results
- ANL: 1200 /µL
- Platelets: 105,000 /µL
- Hemoglobin: 11.9 g/dL
- LDH: 335 U/L
- eGFR: 75 mL/min/1.732
- Imaging: PET/CT reveals inguinal lymphadenopathy, with largest mass 8.5 cm
Treatment and disease history
- Front-line BR
- Completed 6 cycles, achieved PR by 3 months
- Maintained PR for 20 months before developing fever and mediastinal lymphadenopahty
- Second-line R-CHOP
- Competed 6 cycles, achieved PR at 3 months
- PR maintained for 5 months
- Time since completion of last treatment: 5 months
Current treatment
- Started on single-agent idelalisib 150 mg twice a day
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma
February 27th 2024If FDA-approved, epcoritamab would be the first and only subcutaneous bispecific antibody indicated for the treatment of adult patients with relapsed/refractory follicular lymphoma after 2 rounds of previous therapy.
Read More
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
January 12th 2024In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.
Read More
Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma
December 11th 2023Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Read More
